S Siena

Summary

Affiliation: Niguarda Hospital
Country: Italy

Publications

  1. ncbi request reprint Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
    Andrea Sartore-Bianchi
    Divisione Oncologia Falck, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
    J Clin Oncol 25:3238-45. 2007
  2. ncbi request reprint Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
    Stefano Cascinu
    Polytechnic University of Marche Riuniti Hospital Umberto I GM Lancisi G Salesi of Ancona, 60020 Ancona, Italy
    Lancet Oncol 9:39-44. 2008
  3. pmc Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer
    Andrea Sartore-Bianchi
    The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    PLoS ONE 4:e7287. 2009
  4. pmc Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer
    Salvatore Siena
    Ospedale Niguarda Ca Granda, Milan, Italy
    PLoS ONE 8:e62264. 2013
  5. pmc Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study
    Stefania Gori
    Oncologia Medica, Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia, Perugia, Italy
    BMC Cancer 12:158. 2012
  6. ncbi request reprint Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy
    Salvatore Siena
    Dipartimento di Oncologia ad Ematologia, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, I 20162 Milan, Italy
    Crit Rev Oncol Hematol 48:S39-47. 2003
  7. pmc Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
    S Siena
    Ospedale Niguarda Ca Granda, Milan, Italy
    Br J Cancer 97:1469-74. 2007
  8. pmc Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer
    Salvatore Siena
    The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
    J Natl Cancer Inst 101:1308-24. 2009
  9. pmc Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study
    S Siena
    Divisione Oncologia Falck, Ospedale Niguarda Ca Granda, Milan
    Ann Oncol 21:655-61. 2010
  10. doi request reprint Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication
    Salvatore Siena
    Division of Medical Oncology Falck, Niguarda Ca Granda Hospital, Milan, Italy
    Cancer 116:1827-37. 2010

Detail Information

Publications61

  1. ncbi request reprint Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
    Andrea Sartore-Bianchi
    Divisione Oncologia Falck, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
    J Clin Oncol 25:3238-45. 2007
    ..The present study was aimed at assessing the predictive role of EGFR GCN, in terms of clinical outcome, in patients treated with panitumumab...
  2. ncbi request reprint Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
    Stefano Cascinu
    Polytechnic University of Marche Riuniti Hospital Umberto I GM Lancisi G Salesi of Ancona, 60020 Ancona, Italy
    Lancet Oncol 9:39-44. 2008
    ..The aim of this study was to assess the activity and feasibility of a combination of cetuximab with gemcitabine and cisplatin compared with use of gemcitabine and cisplatin alone for the treatment of advanced pancreatic cancer...
  3. pmc Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer
    Andrea Sartore-Bianchi
    The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    PLoS ONE 4:e7287. 2009
    ....
  4. pmc Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer
    Salvatore Siena
    Ospedale Niguarda Ca Granda, Milan, Italy
    PLoS ONE 8:e62264. 2013
    ..The combination of lenalidomide and cetuximab appeared to be well tolerated but did not have clinically meaningful activity in KRAS-mutant metastatic colorectal cancer patients...
  5. pmc Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study
    Stefania Gori
    Oncologia Medica, Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia, Perugia, Italy
    BMC Cancer 12:158. 2012
    ..The prognosis of pT1a-pT1b breast cancer (BC) used to be considered very good, with a 10-y RFS of 90%. However, some retrospective studies reported a 10-y RFS of 81%-86% and suggested benefit from adjuvant systemic therapy...
  6. ncbi request reprint Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy
    Salvatore Siena
    Dipartimento di Oncologia ad Ematologia, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, I 20162 Milan, Italy
    Crit Rev Oncol Hematol 48:S39-47. 2003
    ..These novel cytokines have the potential to simplify the management of neutropenia and anaemia with fewer injections and less disruption to patients daily lives...
  7. pmc Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
    S Siena
    Ospedale Niguarda Ca Granda, Milan, Italy
    Br J Cancer 97:1469-74. 2007
    ..Overall survival favoured no PD patients vs PD patients alive at week 8. Lack of disease progression was associated with better symptom control, HRQoL, and OS...
  8. pmc Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer
    Salvatore Siena
    The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
    J Natl Cancer Inst 101:1308-24. 2009
    ..The use of KRAS mutations as a selection biomarker for anti-EGFR monoclonal antibody (eg, panitumumab or cetuximab) treatment is the first major step toward individualized treatment for patients with metastatic colorectal cancer...
  9. pmc Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study
    S Siena
    Divisione Oncologia Falck, Ospedale Niguarda Ca Granda, Milan
    Ann Oncol 21:655-61. 2010
    ..This phase II study evaluated the efficacy of single-agent therapy with alternating weekly, dose-dense temozolomide in pretreated patients with brain metastases prospectively stratified by primary tumor type...
  10. doi request reprint Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication
    Salvatore Siena
    Division of Medical Oncology Falck, Niguarda Ca Granda Hospital, Milan, Italy
    Cancer 116:1827-37. 2010
    ....
  11. ncbi request reprint Cetuximab for treatment of metastatic colorectal cancer
    G Cerea
    The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    Ann Oncol 17:vii66-7. 2006
    ....
  12. ncbi request reprint High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer
    P Pedrazzoli
    SC Oncologia Medica Falck, Dipartimento Oncologico, Ospedale Niguarda Ca Granda, 1 20162 Milano, Italy
    J Chemother 16:108-11. 2004
    ..They also discuss what may be the attitude to take in our everyday clinical practice, taking into account the availability of new chemotherapeutic agents and targeted therapies...
  13. ncbi request reprint Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer
    A Sartore-Bianchi
    Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
    Ann Oncol 17:ii49-51. 2006
  14. ncbi request reprint High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
    P Pedrazzoli
    Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milano, Italy
    Ann Oncol 17:1479-88. 2006
    ..In this article, we critically review and comment on the data from studies of high dose chemotherapy so far reported in adult patients with small cell lung cancer, ovarian cancer, germ cell tumors and sarcomas...
  15. ncbi request reprint Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies
    Paolo Pedrazzoli
    Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
    Cancer 94:2409-15. 2002
    ..The objectives of the current study were to evaluate the feasibility of this approach in terms of toxicity and engraftment and to document evidence of GVT effects...
  16. ncbi request reprint Rationale and clinical results of multi-target treatments in oncology
    A Sartore-Bianchi
    The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    Int J Biol Markers 22:S77-87. 2007
    ..This review will deal with the rationale underlying the multi-targeted approach and with the available clinical experience with multi-targeted agents, especially focusing on molecules with anti- EGFR mechanisms of action...
  17. ncbi request reprint Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
    Mauro Moroni
    The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    Lancet Oncol 6:279-86. 2005
    ..The molecular mechanisms underlying clinical response or resistance to these agents are unknown...
  18. doi request reprint Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer
    A Sartore-Bianchi
    The Falck Division of Medical Oncology, Department of Oncology, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, Milan, Italy
    Cancer Treat Rev 36:S1-5. 2010
    ..This review will focus on current knowledge regarding the molecular landscape of mCRC including and beyond KRAS, and will summarize novel rationally-developed combinatorial regimens that are being evaluated in early clinical trials...
  19. ncbi request reprint Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy
    S Siena
    Falck Division of Medical Oncology, Department of Hematology and Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    J Clin Oncol 18:1360-77. 2000
    ..To review recent advances in peripheral-blood progenitor-cell (PBPC) transplantation in order to define the optimal cell dose required for autologous and allogeneic transplantation...
  20. ncbi request reprint Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors
    M Moroni
    The Falck Division of Medical Oncology, Department of Oncology and Hematology, Ospedale Niguarda Ca Granda, I 20162 Milan, Italy
    Clin Cancer Res 7:2770-5. 2001
    ....
  21. ncbi request reprint Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen: a phase II study
    M Moroni
    Divisione Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 1 20162 Milano, Italy
    J Chemother 15:394-9. 2003
    ..BMV, administered second-line in an outpatient setting, has activity similar to that of the taxanes, but with a more acceptable toxicity profile including an absence of alopecia...
  22. ncbi request reprint GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia
    I Turin
    Immunology Laboratory and Pediatric Hematology Oncology, IRCCS Policlinico San Matteo, Milan, Italy
    Cytotherapy 9:499-507. 2007
    ..We have now investigated the possibility of producing large amounts of autologous anti-tumor CTL, in compliance with good manufacturing practices, for in vivo use...
  23. ncbi request reprint Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999
    P Pedrazzoli
    S C Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
    Bone Marrow Transplant 32:489-94. 2003
    ..Outcome of patients with IBC is encouraging, suggesting the need for randomized trials. Patients with metastatic disease responding to pretransplant chemotherapy and harboring ER+ tumors have a better outcome...
  24. ncbi request reprint Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors
    S Siena
    Cristina Gandini Unit, Istituto Nazionale Tumori, Milan, Italy
    Exp Hematol 21:1583-90. 1993
    ....
  25. ncbi request reprint Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low f
    R Mortarini
    Division of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Res 57:5534-41. 1997
    ..These results suggest that CD34+- and monocyte-derived DCs are not functionally equivalent APCs for the activation of low-frequency peptide-specific CTLps...
  26. ncbi request reprint PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
    Andrea Sartore-Bianchi
    The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    Cancer Res 69:1851-7. 2009
    ..When the molecular status of the PIK3CA/PTEN and KRAS pathways are concomitantly ascertained, up to 70% of mCRC patients unlikely to respond to EGFR moAbs can be identified...
  27. ncbi request reprint A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer
    Salvatore Siena
    Divisione Oncologia Medica Falck, Dipartimento di Oncologia ed Ematologia, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, I 20162 Milan, Italy
    Oncol Rep 10:715-24. 2003
    ..Pegfilgrastim may offer patients more effective protection against neutropenic complications of chemotherapy with fewer injections and less disruption to their lives...
  28. ncbi request reprint Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy
    Simona Secondino
    Oncologia Medica Falck, Ospedale Niguarda Ca Granda, 20162 Milano, Italy
    Anticancer Res 28:3991-2. 2008
    ....
  29. ncbi request reprint Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia
    Paolo Pedrazzoli
    The Falck Division of Medical Oncology, Niguarda Ca Granda Hospital, Milan, Italy
    Cancer 115:1169-73. 2009
    ..In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue...
  30. ncbi request reprint Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusion
    Roberta Schiavo
    Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    Anticancer Res 27:3273-8. 2007
    ..In the present study, we report the establishment and characterization of a primary Ewing's sarcoma cell line (LDS-Falck 01)...
  31. doi request reprint Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia
    Ilaria Schiavetto
    Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
    Chemotherapy 54:417-20. 2008
    ..In this article, we review and discuss the role of iron supplementation in the setting of chemotherapy-related anemia in view of recently published clinical trials addressing this issue...
  32. ncbi request reprint EGFR FISH in colorectal cancer: what is the current reality?
    Mauro Moroni
    Falck Division of Medical Oncology, Niguarda Ca Granda Hospital, 20162 Milan, Italy
    Lancet Oncol 9:402-3. 2008
  33. ncbi request reprint Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation
    Simona Secondino
    Divisione Oncologica Falck, Ospedale Niguarda Ca Granda, Milan, Italy
    Haematologica 92:418-20. 2007
    ..Our study may suggest that an immune-mediated effect cannot be excluded in some STS...
  34. doi request reprint Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha
    Paolo Pedrazzoli
    Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 20162, Milano, Italy
    J Clin Oncol 26:1619-25. 2008
    ..We have prospectively evaluated whether intravenous iron can increase the proportion of patients with chemotherapy-related anemia who respond to darbepoetin...
  35. ncbi request reprint Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia
    Riccardo Ricotta
    Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milano, Italy
    Future Oncol 2:667-76. 2006
    ..Recent trials have been conducted to evaluate the use of pegfilgrastim in different clinical settings, including support of dose-dense regimens, mobilization and transplantation of hematopoietic stem cells...
  36. ncbi request reprint Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma
    Pier Adelchi Ruffini
    Divisione Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
    Curr Gene Ther 5:511-21. 2005
    ....
  37. ncbi request reprint Treatment of metastatic neuroendocrine carcinomas based on WHO classification
    Salvatore Artale
    Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 1 20162 Milan, Italy
    Anticancer Res 25:4463-9. 2005
    ..Grade 3-4 side-effects were limited to 9% thrombocytopenia and 12.5% neutropenia. Both these treatment regimens had a good therapeutic index and compared favourably with those previously reported for metastatic WD-NECs and PD-NECs...
  38. ncbi request reprint Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
    Andrea Sartore-Bianchi
    The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    Target Oncol 5:19-28. 2010
    ..We suggest that in the near future comprehensive molecular analysis of the entire oncogenic pathway triggered by the EGFR should be performed, thus enhancing the prediction ability of individual markers...
  39. doi request reprint T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results
    S Secondino
    Falck Medical Oncology, Niguarda Ca Granda Hospital, Milano, Italy
    Ann Oncol 23:435-41. 2012
    ..With the aim of favoring in vivo T-cell expansion, we optimized our cell therapy approach by administering higher doses of EBV-specific CTLs, following lymphodepleting chemotherapy...
  40. ncbi request reprint The effect of anticonvulsant drugs on blood levels of methotrexate
    M Riva
    Department of Neurology, Niguarda Ca Granda Hospital, Milan, Italy
    J Neurooncol 48:249-50. 2000
    ..We report how even the results of high dose sequential chemotherapy can be influenced by antiepileptic drugs...
  41. ncbi request reprint Survival of adults treated for medulloblastoma using paediatric protocols
    Filippo Spreafico
    Paediatric Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Eur J Cancer 41:1304-10. 2005
    ....
  42. ncbi request reprint New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia
    S Siena
    Divisione Oncologia Medica Falck, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
    Haematologica 84:369-72. 1999
    ..Molecular analysis of the t(5;10)(q33;q22) translocation breakpoint is currently underway in order to identify genes located in this region which might provide insights into the pathogenesis of atypical myeloproliferative disorders...
  43. ncbi request reprint Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors
    M Renga
    Divisione Oncologia Medica Falck, Dipartimento di Oncologia ed Ematologia, Ospedale Niguarda Ca Granda, Milan, Italy
    Ann Oncol 14:1177-84. 2003
    ..In the present article we review the biological basis, development and early clinical results of this novel immunotherapeutic approach for solid tumors...
  44. ncbi request reprint Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodies
    Salvatore Siena
    Falck Division of Medical Oncology, Department of Oncology and Hematology, Niguarda Ca Granda Hospital, Milan, Italy
    Suppl Tumori 1:S46-8. 2002
  45. doi request reprint Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer
    Salvatore Artale
    J Clin Oncol 26:4217-9. 2008
  46. doi request reprint Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
    ..Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials...
  47. ncbi request reprint Iron supplement in cancer patients receiving erythropoietin
    Paolo Pedrazzoli
    J Clin Oncol 22:4428; author reply 4428-9. 2004
  48. ncbi request reprint Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    David Cunningham
    Royal Marsden Hospital, London, United Kingdom
    N Engl J Med 351:337-45. 2004
    ..We compared the efficacy of cetuximab in combination with irinotecan with that of cetuximab alone in metastatic colorectal cancer that was refractory to treatment with irinotecan...
  49. ncbi request reprint Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
    Johan Vansteenkiste
    Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    J Natl Cancer Inst 94:1211-20. 2002
    ..This phase III study compared the safety and efficacy of darbepoetin alfa with placebo in patients with lung cancer receiving chemotherapy...
  50. ncbi request reprint Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial
    Luigi Dogliotti
    Unit of Medical Oncology, University of Torino, San Luigi Hospital, Orbassano Torino, Italy
    Eur Urol 52:134-41. 2007
    ....
  51. ncbi request reprint Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
    Silvia Benvenuti
    Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo, Italy
    Cancer Res 67:2643-8. 2007
    ..They also provide the rationale for combination therapies, targeted simultaneously to the EGFR and RAS/RAF/MAPK signaling pathways in CRC patients...
  52. ncbi request reprint Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 25:1658-64. 2007
    ..We compared the activity of panitumumab plus best supportive care (BSC) to that of BSC alone in patients with metastatic colorectal cancer who had progressed after standard chemotherapy...
  53. ncbi request reprint Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units
    Lara Maria Pasetto
    Oncologia Medical 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy
    Anticancer Res 28:1813-20. 2008
    ..In this paper, we highlight the pattern of palliative treatment and possible effects on survival among elderly patients...
  54. ncbi request reprint HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
    Roman Perez-Soler
    Department of Oncology, Hofheimer 100, Montefiore Medical Center Albert Einstein College of Medicine, 111 East 210th Street, Bronx, New York 10467, USA
    Oncologist 10:345-56. 2005
    ..The increasing use of HER1/EGFR-targeted agents makes managing rash important. We hope the outcomes from this Forum provide background for future studies...
  55. ncbi request reprint Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation
    Jacopo Peccatori
    Hematology Bone Marrow Transplant Unit, Istituto Scientifico H San Raffaele, Milano, Italy
    Cancer 104:2099-103. 2005
    ..The objective of this study was to identify prognostic factors for predicting survival in patients with advanced renal cell carcinoma (RCC) who had undergone an allogeneic stem cell transplantation after failure on immunotherapy...
  56. ncbi request reprint [4th National Conference of Medical Oncology. Evolution of the technology and clinical objectives of antitumor therapy]
    Salvatore Siena
    SC Divisione Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano
    Tumori 88:A1-4. 2002
  57. ncbi request reprint Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling
    Daniela Montagna
    Immunology Laboratory and Pediatric Hematology Oncology, IRCCS Policlinico San Matteo, University of Pavia, Piazzale Golgi, 27100 Pavia, Italy
    Int J Cancer 110:76-86. 2004
    ..Altogether these results demonstrate that our experimental approach is suitable for efficiently generating and expanding anti-solid tumor CTL to be used for adoptive immunotherapy...
  58. ncbi request reprint Colorectal cancer treatment in elderly patients: results of a retrospective analysis addressed to the chiefs of medical oncology units in Italy
    Lara Maria Pasetto
    Istituto Oncologico Veneto, IRCCS, Oncologia Medica 2, Padova, Italy
    Anticancer Res 27:3601, 3603-8. 2007
    ..The aim of this retrospective analysis was to evaluate the differences of 1-year treatment and chemotherapy related-toxicity in elderly colorectal cancer (CRC) patients in different Italian medical oncology units...
  59. ncbi request reprint Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis
    Vittorio Perfetti
    Amyloid Center, IRCCS Policlinico S Matteo P le Golgi 2, 27100 Pavia, Italy
    Haematologica 91:1635-43. 2006
    ..Refined selection of patients suitable for transplantation and personalized adaptation of the doses of melphalan might improve the outcome...
  60. ncbi request reprint Absence of c-Kit and members of the epidermal growth factor receptor family in refractory germ cell cancer
    Mauro Moroni
    Cancer 97:2926-7; author reply 2927-8. 2003
  61. ncbi request reprint Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes
    Patrizia Comoli
    Laboratorio di Ricerca Area Trapianti e Oncoematologia Pediatrica, IRCCS Policlinico S Matteo, V le Golgi 19, 27100 Pavia, Italy
    J Clin Oncol 23:8942-9. 2005
    ..We conducted a clinical trial of EBV-targeted cell therapy with autologous virus-specific cytotoxic T lymphocytes (CTLs) for NPC refractory to conventional treatments...